Exact Sciences Corporation
Exact Sciences Corporation (EXAS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · EXAS · as of Jun 8, 2026
Key Statistics
Explore Exact Sciences Corporation Data
exas stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 41 · Buy rate: 53.7%
The EXAS analyst consensus is Buy, based on ratings from 41 Wall Street analysts over the past 3 months. The average 12-month price target is $105.00, representing +0.09% upside from the current price of $104.91.
Competitors & Peers
exas competitorsEXAS
BBIO
DOCS
GH
ICLR
QGENStock Performance
Full HistoryAbout Exact Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test …
what is exact sciences corporation · exas stock overview · exact sciences corporation company profile · who is exact sciences corporation ceo · exas NASDAQ · exact sciences corporation headquarters · exact sciences corporation business segments
About Stock Overview & Key Data
Exact Sciences Corporation (EXAS) is a Healthcare company in the Medical - Diagnostics & Research industry, listed on NASDAQ since Feb 1, 2001. As of the latest trading session, EXAS stock price is $104.91, with a market capitalization of $20.0B. The stock has returned +137.62% over the past 12 months and +3.30% year-to-date.
According to 41 Wall Street analysts, the consensus rating for Exact Sciences Corporation stock is Buy, with an average 12-month price target of $105.00. In fiscal year 2025, Exact Sciences Corporation reported revenue of $3.2B and net income of -$207.9M. For detailed data — including Exact Sciences Corporation revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Exact Sciences Corporation (EXAS) stock price is $104.91. The stock is traded on NASDAQ under the ticker symbol EXAS. The 52-week range is $38.81 – $104.98.